Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
|
27793035 |
2016 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2.
|
27836010 |
2016 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
|
27257965 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Since germline mutations of BRCA1 often lead to breast tumors that are triple-negative breast cancer (TNBC) type, we aimed to investigate whether genetic deficiency in genes of the BRCA1-A complex is associated with risk to TNBC development.
|
26848770 |
2016 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.
|
26629949 |
2016 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Little is known about miRNA deregulation in hereditary breast tumors as no miRNA expression profiling studies have been performed in normal breast tissue of BRCA1 and BRCA2 mutation carriers. miRNA profiles of 17 BRCA1- and 9 BRCA2-associated breast carcinomas were analyzed using microarrays.
|
26378051 |
2015 |
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Integrated analysis of the global gene methylation and expression profiles of a set of 33 familial breast tumours revealed that FOXA1 promoter methylation is inversely correlated with the transcriptional expression of FOXA1 and that BRCA1 mutation breast cancer is significantly associated with FOXA1 methylation and downregulation of FOXA1 expression, providing physiological evidence to our findings that FOXA1 expression is regulated by methylation and chromatin silencing and that BRCA1 maintains FOXA1 expression through suppressing FOXA1 gene methylation in breast cancer.
|
25531315 |
2015 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
For this purpose, genomic and gene expression profiles of basal-like BRCA1-mutated breast tumors (n = 27) were compared with basal-like familial BRCAX (non-BRCA1/2/CHEK2*1100delC) tumors (n = 14) in a familial cohort of 120 breast carcinomas.
|
25616998 |
2015 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Does familial breast cancer and thymoma suggest a cancer syndrome? A family perspective.
|
26344711 |
2015 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A set of 16 miRNAs differentially expressed between BRCA 1/2-related and BRCAX breast tumors emerged from the profile analysis.
|
25333258 |
2015 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
These results validate the concept of using pigs as a model to study BRCA1 defects in breast cancer and establish the first porcine breast tumor cell line.
|
26379698 |
2015 |
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Constitutive AhR expression coupled to BRCA-1 promoter CpG hypermethylation may be predictive markers of ERα-negative breast tumor development.
|
26715507 |
2015 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Using a one-step TaqMan-based qRT-PCR, 5 commonly used reference genes (ACTB, GAPDH, RPLPO, GUSB, and TFRC) and 10 anticancer drug-related genes (TYMS, RRM1, TUBB3, STMN1, TOP2A, EGFR, VEGFR2, HER2, ERCC1, and BRCA1) were analyzed in 327 tissue samples from lung, rectal, colon, gastric, esophageal, and breast tumors.
|
25445497 |
2015 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
|
25863477 |
2015 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We selected 150 FFPE breast tumor DNA samples [47 BRCA1 pathogenic mutation carriers, 65 BRCAx (BRCA1-wild type), 38 BRCA1 test variants] and analyzed a subset (n=54) using the Illumina 450K methylation platform, using the remaining samples for bisulphite pyrosequencing validation.
|
26727311 |
2015 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.
|
24917463 |
2015 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The gene expression profiles of TNBCs are similar to those of breast tumours in women with BRCA1 mutations.
|
25682074 |
2015 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Moreover, numerous studies demonstrated the methylation status of CpG islands in the promoter regions of BRCA1 gene was aberrant in patients with sporadic breast tumors compared with healthy females or patients with benign diseases.
|
26643130 |
2015 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment.
|
25992773 |
2015 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Gene expression profiling studies have disclosed specific molecular signatures for BRCA1/2-related breast tumors as compared to sporadic cases, which might help diagnosis and clinical follow-up.
|
26061043 |
2015 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation.
|
25857409 |
2014 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although the BD-L signature is present in all subtypes of breast cancer, it is significantly higher in BRCA1 mutant primary tumors as compared with sporadic breast tumors.
|
24625110 |
2014 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Poly(ADP-ribose) polymerase (PARP) inhibitors are promising targeted treatment options for hereditary breast tumors with a homologous recombination (HR) deficiency caused by BRCA1 or BRCA2 mutations.
|
24963051 |
2014 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Sporadic basal-like cancers (BLCs) are a common subtype of breast cancer that share multiple biological properties with BRCA1-mutated breast tumors.
|
25092866 |
2014 |
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Our findings suggest that a small proportion of normal breast epithelial cells with BRCA1 promoter methylation can be precursor cells from which BRCA1-methylated breast tumors may originate.
|
25155055 |
2014 |